Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS-PPX: Fitusiran Switching Study in Hemophilia A and B
NCT03549871Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2018
- Primary completion
- Jan 2022
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 15
01
Overview
A Phase 3 trial of fitusiran in hemophilia A, hemophilia B (HB), sponsored by Sanofi. Started Jul 2018; status: completed.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT03549871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549871.